Silence Therapeutics plc
SLN
$5.35
-$0.11-2.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.59% | -14.40% | 41.45% | -41.95% | -36.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.59% | -14.40% | 41.45% | -41.95% | -36.75% |
| Cost of Revenue | -37.41% | -5.67% | -4.12% | -28.40% | -41.42% |
| Gross Profit | 72.67% | -18.16% | 72.77% | -53.26% | -32.58% |
| SG&A Expenses | 7.12% | 17.44% | 7.88% | 6.21% | -0.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.10% | 33.93% | 9.35% | -14.28% | -26.70% |
| Operating Income | -48.99% | -73.67% | 9.87% | -2.09% | 20.68% |
| Income Before Tax | -74.83% | -74.93% | 20.45% | -12.17% | 26.63% |
| Income Tax Expenses | -25.97% | 16.72% | 364.91% | 158.47% | 172.65% |
| Earnings from Continuing Operations | -61.44% | -69.01% | 12.09% | -43.58% | -0.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.44% | -69.01% | 12.09% | -43.58% | -0.10% |
| EBIT | -48.99% | -73.67% | 9.87% | -2.09% | 20.68% |
| EBITDA | -49.67% | -74.82% | 9.97% | -2.06% | 20.98% |
| EPS Basic | -42.08% | -36.19% | 30.01% | -16.55% | 14.46% |
| Normalized Basic EPS | -52.07% | -39.53% | 37.26% | 10.96% | 37.75% |
| EPS Diluted | -42.08% | -36.19% | 30.01% | -16.55% | 14.46% |
| Normalized Diluted EPS | -52.07% | -39.53% | 37.26% | 10.96% | 37.75% |
| Average Basic Shares Outstanding | 13.08% | 20.41% | 24.68% | 21.50% | 18.36% |
| Average Diluted Shares Outstanding | 13.08% | 20.41% | 24.68% | 21.50% | 18.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |